| 31 Jul 2008 |
|
Health Ministry decides to limit use of drug for blood-thinning in UAE
- Text size
ABU DHABI - A drug that is said to have caused deaths and allergic reactions to a number of people in the United States and Europe, will not be pulled out of the UAE market due to studies indicating that the level of the drug's impurity in the country is harmless, according to an announcement of the Ministry of Health (MoH).Ministry of Health (MoH).
The ministry said that three slightly contaminated batches of a drug belonging to the Heparin group were detected in the country. Heparin drugs, which are produced by various pharmaceutical companies, are a group of blood thinners used to treat certain heart conditions such as heart attacks and to prevent abnormal blood clotting.
After consultations with the company that produces the widely-used heparin drug called Clexane, the MoH has decided against pulling the contaminated batches of the drug out of the market opting instead to limit its usage.
The ministry issued a circular to all healthcare institutions in the country asking them to stop injecting the drug intravenously, and administer it exclusively through under the skin injections (subcutaneously).
According to Dr Amin Al Amiri, CEO of Medical Practice and Licensing at the MoH, the ministry's decision came after the assessment of the position of local health authorities in various European countries, including the UK and France, who also opted not to pull the drug out of the market.
The United States controversy was regarding another Heparin drug manufactured by the pharmaceutical company Baxter International, which caused the death of around 81 people.
The United States Food and Drug Administration (FDA) reported that since the end of 2007, it received about 350 reports of health problems associated with Baxter's multiple dose injectable heparin. Reactions included difficulty breathing, nausea, vomiting, excessive sweating, and rapidly falling blood pressure.
Investigations by the FDA and Baxter revealed that the source of the contamination was most likely a Chinese manufacturer of the active pharmaceutical ingredient found in the drug.
Since most of the raw material for making all Heparin drugs comes from China, companies producing Heparin drugs with ingredients imported from China remain succeptible to receiving contaminated batches.
"The ministry decided to go an extra mile by limiting the drug's administration to under the skin injections, as over 95 per cent of adverse reactions to other Heparin drugs were reported after administration of the drug through the vein," he said.
Dr Mahmoud explained that the decision of some European countries to keep the drug in the market was made because these authorities decided no other drug would compensate for Clexane's medical usage.
"Clexane is showing a clinical advantage, and cannot be substituted by other heparin brands. Although some European countries decided to recall the drug, this was not due to any reported side-effects", he said.
Physicians in the country are urged to report all unexpected side-effects of all drugs to health authorities, such as the Abu Dhabi and Dubai health authorities and the MoH.
By Asma Hamid
© Khaleej Times 2008
Zawya is a distributor (and not a publisher) of content supplied by third parties and subscribers. Any opinions, advice, statements, services, offers, or other information or content expressed or made available by those third parties, including information providers, subscribers or other users of the Service, are those of the respective author(s) or distributor(s) and not of the Company. The Company neither endorses nor is responsible for the accuracy or reliability of any opinion, advice or statement made on the Service by anyone other than authorized Service employee spokespersons while acting in their official capacities. The Company is not responsible for any infringement of intellectual property rights or breach of any applicable law or regulation, including regulation in relation to financial services or the distribution of financial products, defamation, data protection, telecommunications (including regulations relating to excessive use, spamming or other abusive activities) or obscene, offensive or illegal content). Under no circumstances will the Company be liable for any loss or damage caused by a member's reliance on information obtained through the Service. It is the responsibility of member to evaluate the accuracy, completeness or usefulness of any information, opinion, advice or other content available through the Service. Please seek the advice of professionals, as appropriate, regarding the evaluation of any specific information, opinion, advice or other content.
Read the full Member Agreement
http://www.zawya.com/legal/NewsLetter.cfm?name=disclaimer
Loading ...
Post a Comment
1.1 Contain any material which is libelous or defamatory of any person, is obscene, offensive, hateful or inflammatory or causes damage to the reputation of any person or organisation.
1.2 Promote sexually explicit material, violence, discrimination based on race, sex, religion, nationality, disability, sexual orientation or age or any illegal activity.
1.3 Be made in breach of any legal duty owed to a third party, such as a contractual duty or a duty of confidence.
1.4 Be threatening, abuse or invade another's privacy, or cause annoyance, inconvenience or needless anxiety.
1.5 Be used to impersonate any person, to misrepresent your identity or affiliation with any person, or be likely to deceive any person.
1.6 Give the impression that they represent Zawya.
1.7 Advocate, promote or assist any unlawful act such as (by way of example only) copyright infringement or computer misuse.